

Edgar Filing: PROVECTUS PHARMACEUTICALS INC - Form 8-K

PROVECTUS PHARMACEUTICALS INC
Form 8-K
October 07, 2005

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): October 7, 2005

PROVECTUS PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Charter)

| | | |
|---|-----------------------------|--|
| Nevada | 0-9410 | 90-0031917 |
| (State or Other Jurisdiction of Incorporation or Organization) | (Commission File Number) | (I.R.S. Employer Identification Number) |
| 7327 Oak Ridge Highway, Suite A, Knoxville, Tennessee | | 37931 |
| (Address of Principal Executive Offices) | | (Zip Code) |
| Registrant's telephone number, including area code: | 865/769-4011 | |

(Former Name or Former Address, if Changed Since Last Report)

Item 8.01. Other Events.

Provectus Pharmaceuticals, Inc., announced that Professor John F Thompson, MD, Director of the Sydney Melanoma Unit, Camperdown, NSW, Australia, discussed preliminary results from the metastatic melanoma clinical trial he is conducting using the Company's lead cancer agent, PV-10. Professor Thompson made his remarks at The William and Ida Friday Center for Continuing Education of The University of North Carolina at Chapel Hill on October 6, 2005, as part of the course "Current Management of Melanoma: A Multidisciplinary Perspective." The Company expects additional information on this clinical study (PV-10-MM-01, details available at www.ClinicalTrials.gov) to be available in early 2006.

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Provectus Pharmaceuticals, Inc.

Dated: October 7, 2005

By: /s/ H. Craig Dees

H. Craig Dees
Chief Executive Officer